JNJ Q1 results: there’s positive narratives in all three of our segments

Shares of Johnson & Johnson (NYSE: JNJ) are down 1.0% in premarket trading on Tuesday after the U.S. company reported weaker-than-expected Q1 revenue and lowered its guidance for the future.

J&J Q1 financial highlights

Net income printed at $5.15 billion that translates to $1.93 per share.
In Q1 last year, it had reported $6.20 billion profit or $2.32 per share.
Adjusted for one-time items, J&J earned $2.67 per share.
Sales jumped 5.0% YoY in the first quarter to $23.43 billion.
FactSet consensus was for $2.59 of adjusted EPS on $23.62 billion in sales.
Pharamceutical sales were up 6.3% but missed estimates by $0.6 billion.

COVID-19 vaccine sales sunk to $75 million in the U.S. from $100 million. Moving forward, the New Jersey-headquartered company won’t be offering guidance for the COVID-19 vaccine sales. On CNBC’s “Squawk Box”, CFO Joseph Wolk said:

The slight miss was around the COVID vaccine. But our vaccine was not for profit. We gave guidance for it last year because Street expected it. Suspending guidance allows investors to focus on what’s driving value today and in the future. That’s our core portfolio.

Future guidance and dividend

For fiscal 2022, Johnson & Johnson now forecasts revenue to fall in the range of $94.8 billion to $95.8 billion. It expects $10.15 to $10.35 of adjusted EPS this year, as per the earnings press release. CFO Wolk added:

We think it was a solid start amongst a number of dynamics that are going on across all industries. But there’s positive narratives in all three of our segments. Medical technology really led the growth of the company. We saw uptick in surgical procedures.

The finance chief also confirmed that the pharmaceutical segment picked up again after a hit due to the Omicron variant at the start of the first quarter.

Wolk agreed supply constraints weighed on the consumer segment but expects supply chain to improve throughout the rest of the year. Also on Tuesday, J&J announced a 6.6% increase in its quarterly dividend.

The post JNJ Q1 results: there’s positive narratives in all three of our segments appeared first on Invezz.

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 All Rights Reserved.

To Top